Alopecia Areata: A Comprehensive Review of Clinical, Immunologic, and Genetic Perspectives

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

This study found that patients with alopecia areata had a significantly different gut microbiota composition compared to healthy controls, suggesting possible microbiota involvement in the disease's pathogenesis.

This study found that young patients with severe AA are more prone to nail abnormalities such as pitting and leukonychia, with koilonychia and red spots lunula in more severe cases.

This review suggests that the gut microbiome and metabolome may play a significant role in alopecia areata and emphasizes the potential of targeting these factors for improved prevention, diagnosis, and treatment strategies for this skin condition.

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.

This review discusses recent advances in understanding and treating alopecia areata, emphasizing the ongoing challenges and unmet needs in disease management; it reports no new clinical findings.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This review summarizes the influences of lifestyle factors such as smoking, alcohol, and diet on the pathogenesis of alopecia areata but reports no new clinical results.

This review discusses the relationship between gut microbiota and alopecia areata, and it does not report new clinical results.

This review discusses current and emerging therapies for alopecia areata, highlights the challenges in managing this chronic disease, and emphasizes the importance of addressing its psychosocial impacts; it reports no new clinical results.

This study reviews the epidemiology of alopecia areata in the UK, focusing on its links to mental health comorbidities, autoimmune/atopic associations, and common infection incidences.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

This review explores the efficacy and outcomes of using JAK inhibitors for treating alopecia areata, noting advancements in understanding the disease's pathomechanisms and suggesting that JAK inhibitors may offer targeted therapeutic benefits by blocking specific inflammatory pathways involved in this chronic condition.

This study found that topical corticosteroids are the most supported first-line treatment for pediatric alopecia areata, with contact immunotherapy as the next best option.

This article reviews alopecia areata as a chronic autoimmune disease affecting hair follicles and discusses its association with other autoimmune conditions, but provides no new clinical findings.

This review explores the autoimmune hypothesis of alopecia areata and the possible genetic and melanogenesis-associated autoantigens, but reports no new clinical findings.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This study identified specific miRNAs that are potentially linked to severe active alopecia areata, suggesting they could be targets for future treatment development.

This study found that JAK inhibitors for alopecia areata showed promising response rates, with 72.4% of 289 cases responding, and oral administration achieving better outcomes than topical treatment, but recurrence occurred when treatment stopped. Further large-scale studies are needed to confirm these findings.

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

This study found that MDSC exosomes promoted partial hair regrowth and modulated immune responses in mice with alopecia areata, suggesting potential as a treatment for autoimmune diseases.

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

Most people with alopecia areata have nail changes, which are common but don't greatly affect their quality of life.

This review discusses the clinical characteristics, diagnosis, and treatment of alopecia areata, exploring potential environmental, immunological, and genetic factors involved in its development, but reports no new research findings.

Certain microRNAs may help treat alopecia areata by targeting immune pathways.

This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.

This review discusses squaric acid dibutylester's use, effects, and safety in treating alopecia areata, but reports no new clinical results.

This review discusses alopecia areata, highlighting its autoimmune aspects, environmental triggers, and current treatment options, but reports no new clinical results; recent studies suggest JAK pathway intervention may offer therapeutic potential.

Leptin helps start the growth phase of hair.

This article proposes that alopecia areata may be caused by immune attacks on hair follicles after an immune privilege collapse, suggesting new therapeutic approaches targeting this immune response pattern.

In this study, researchers found that mouse hair follicles recruit Langerhans cells by secreting chemokines, acting as key portals for these cells in both mice and humans.

This study found that DNA methylation and histone modification status were altered in peripheral blood mononuclear cells of patients with alopecia areata, suggesting these changes may contribute to the disease's pathological immune responses.

This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.

This article reviews the clinical presentation and histopathologic features of alopecia areata and proposes a hypothesis for its development, but it reports no new clinical results.

This study identified four genetic loci on chromosomes 6, 10, 16, and 18 that may contribute to susceptibility for alopecia areata and suggested shared genetic factors with psoriasis.

This case report describes persistent depigmented hair regrowth from an alopecia areata patch, challenging the previous assumption that such regrowth is only temporary.

This report discusses the potential of minoxidil for treating hair loss, spurred by early findings of hair regrowth in some patients, but emphasizes the need for further research to establish its safety and efficacy.